Evaluation of CYP2D6 Oxidation of Dextromethorphan and Propafenone in a Chinese Population with Atrial Fibrillation
- 1 January 2001
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 41 (1) , 92-96
- https://doi.org/10.1177/00912700122009737
Abstract
The objective of this study was to determine the percentage of patients with paroxysmal atrial fibrillation who were poor metabolizers of CYP2D6 in a Chinese population from Hong Kong and to assess the relationship between the dextromethorphan/dextrorphan ratio and the propafenone/5‐hydroxypropafenone ratio or the steady‐state propafenone concentration. Patients (n = 60) were recruited from the Arrhythmia Clinic at the University of Hong Kong and given dextromethorphan 30 mg. The dextromethorphan and dextrorphan concentrations in urine over the next 8 hours were used to determine metabolizer status. If the metabolic ratio was greater than 0.3, the patient was determined to be a poor metabolizer. In phase 2, patients (n = 38) were given propafenone 150 mg twice daily, and at steady state, the propafenone and 5‐OH propafenone plasma concentrations were determined. It was found that 15% of the patients were poor metabolizers of dextromethorphan. There was a significant correlation between the metabolic ratios of dextromethorphan/dextrorphan and propafenone/5‐OH propafenone (r = 0.49, p = 0.0019) and between the dextromethorphan/dextrorphan ratio and the concentration of propafenone (r = 0.32, p = 0.05). No correlations were found in the extensive or poor metabolizer subgroups. It was concluded that the percentage of poor metabolizers in atrial fibrillation patients from Hong Kong was much larger than in previous studies of Chinese patients who were not from Hong Kong. The ability to metabolize dextromethorphan to dextrorphan is related to the ability to metabolize propafenone to 5‐hydroxypropafenone.Keywords
This publication has 20 references indexed in Scilit:
- Propafenone in a usual dose produces severe side‐effects: the impact of genetically determined metabolic status on drug therapyJournal of Internal Medicine, 1995
- Dextromethorphan Polymorphic Hepatic Oxidation (CYP2D6) in Healthy Black American Adult SubjectsTherapeutic Drug Monitoring, 1995
- Normal-phase high-performance liquid chromatographic procedure for the determination of diprafenone in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1989
- Determination of dextromethorphan metabolizer phenotype in healthy volunteersEuropean Journal of Clinical Pharmacology, 1989
- Phenotyping polymorphic drug metabolism in the French Caucasian populationEuropean Journal of Clinical Pharmacology, 1988
- Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.Circulation, 1987
- Clinical pharmacology of propafenone: Pharmacokinetics, metabolism and concentration-response relationsThe American Journal of Cardiology, 1984
- High-performance liquid chromatographic analysis of propafenone in human plasma samplesJournal of Chromatography B: Biomedical Sciences and Applications, 1982